Chemotherapy for advanced pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4 SUPPL., 2003, Pages 16-23

  Haller, Daniel G ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 Fluorouracil; Gemcitabine; Pancreatic cancer; Treatment

Indexed keywords

DRUG DOSAGE; ONCOLOGY; TUMORS;

SYMPTOM CONTROL;

CHEMOTHERAPY;

FLUOROURACIL; GEMCITABINE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; REVIEW; STANDARD;

EID: 0038121455     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00448-6     Document Type: Review

References (44)

1. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 6th ed. Vol. 1. Philadelphia: Lippincott, Williams & Wilkins; 1997. p. 1126-1161.
2. Cancer facts and figures 2003. 2003;American Cancer Society, Atlanta.
3. Burris H.A. III, Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial . J Clin Oncol. 15:1997;2403-2413.
4. Warshaw A.L., Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 326:1992;455-465.
5. Mallinson C.N., Rake M.O., Cocking J.B., et al. Chemotherapy in pancreatic cancer Results of a controlled, prospective, randomised, multicentre trial . BMJ. 218:1980;1589-1591.
6. Cullinan S., Moertel C.G., Wieand H.S., et al. A phase III trial on the therapy of advanced pancreatic carcinoma Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin . Cancer. 65:1990;2207-2212.
7. Casper E.S., Green M.R., Kelsen D.P., et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 12:1994;29-34.
8. Moore M.J., Hamm J., Eisenberg P., et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (pts) with advanced pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;240a.
9. Bramhall S.R., Rosemurgy A., Brown P.D., et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer A randomized trial . J Clin Oncol. 19:2001;3447-3455.
10. Bramhall S.R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 87:2002;161-167.
11. Colucci G., Giuliani F., Gebbia V., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale . Cancer. 94:2002;902-910.
12. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Eastern Cooperative Oncology Group trial E2297 . J Clin Oncol. 20:2002;3270-3275.
13. Van Cutsem E., Karasek P., Oettle H., et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). [Abstract] Proc Am Soc Clin Oncol. 21:2002;130a.
14. Rothenberg M.L., Moore M.J., Cripps M.C., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 7:1996;347-353.
15. Storniolo A.M., Enas N.H., Brown C.A., et al. An investigational new drug treatment program for patients with gemcitabine Results for over 3000 patients with pancreatic carcinoma . Cancer. 85:1999;1261-1268.
16. Manzano H, Esquerdo G, Rifa J, et al. Clinical benefit with gemcitabine (GEM) as a first-line therapy for patients with advanced pancreatic cancer (APC). Proc Eur Soc Med Oncol 1998; Abstr. 253.
17. Karasek P., Nemec J., Bednarik O., et al. Treatment of advanced pancreatic cancer (APC) with gemcitabine as a single agent A multicentre trial . Ann Oncol. 11:(Suppl. 4):2000;66.
18. Aykan F, Argon A, Alici S, et al. A phase II trial of gemcitabine in patients with advanced pancreatic cancer (APC) [Abstract]. Proc Am Soc Clin Oncol 2000;19:314a.
19. Crino L, Mosconi AM, Calandri C, et al. Gemcitabine in advanced pancreatic cancer: A phase II trial [Abstract]. Am J Cancer 1997(Suppl. 8):33.
20. Carmichael J., Fink U., Russell R.C., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 73:1996;101-105.
21. Tempero M., Plunkett W., Ruiz van Haperen V., et al. Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma. [Abstract] Proc Am Soc Clin Oncol. 18:1999;273a.
22. Lencioni M, Falcone A, Masi G, et al. Phase I-II study of gemcitabine (GEM) in combination with 24 hours continuous infusion (CI) of 5-fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with advanced pancreatic cancer (APC) [Abstract]. Ann Oncol 2000;11(Suppl. 4):66.
23. Pastorelli D., Pedrazzoli S., Sperti C., et al. Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC). [Abstract] Proc Am Soc Clin Oncol. 19:2000;284a.
24. Cascinu S., Silva R., Barni S., et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 80:1999;1595-1598.
25. Hidalgo M., Castellano D., Paz-Ares L. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 17:1999;585-592.
26. Rodriguez-Lescure A., Carrato A., Massuti B., et al. Phase I-II study of gemcitabine (GEM) and weekly 48-hour continuous infusion (CI) of high dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC). [Abstract] Proc Am Soc Clin Oncol. 18:1999;298a.
27. Shulman K., Kindler H., Lad T., et al. Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with advanced pancreatic cancer (APC). [Abstract] Ann Oncol. 11:(Suppl. 4):2000;66.
28. Anchisi S., Delaloye B., Petite J., et al. Gemcitabine (GEM) and continuous infusional 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;326a.
29. Riedel C., Wein A., Wehler M., et al. High dose 5-fluorouracil (FU) 24-h-infusion with gemcitabine (GEM) Tolerable and efficient in palliative outpatient treatment of pancreatic cancer . [Abstract] Proc Am Soc Clin Oncol. 19:2000;316a.
30. Rauch D.P., Maurer C.A., Aebi S., et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology. 60:2001;43-48.
31. Louvet C., Hammel P., Andre T., et al. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion and gemcitabine (FOLFUGEM regimen). [Abstract] Proc Am Soc Clin Oncol. 18:1999;275a.
32. Polyzos A., Tsavaris N., Kosmas C., et al. A phase II study of gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;311a.
33. Gremzar® (gemcitabine HCl) package insert. Eli Lilly and Company, Indianapolis: Eli Lilly;1998.
34. Heinemann V., Wilke H., Possinger K., et al. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer Final results of a phase II study . [Abstract] Proc Am Soc Clin Oncol. 18:1999;274a.
35. Philip P.A., Zalupski M., Vaitkevicius V.K., et al. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 18:1999;274a.
36. Colucci G., Riccardi F., Giuliani F., et al. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC) A phase II multicenter study of the Southern Italy Oncology Group . [Abstract] Proc Am Soc Clin Oncol. 18:1999;250a.
37. Rocha Lima C., Savarese D., Bruckner H., et al. Multicenter phase II trial of first-line irinotecan and gemcitabine (IRINOGEM) in patients with locally advanced or metastatic pancreatic cancer (PC). [Abstract] Proc Am Soc Clin Oncol. 19:2000;263a.
38. Stathopoulos G., Rigatos G., Dimopoulos M., et al. Front-line treatment of pancreatic carcinoma with gemcitabine (GMB) in combination with irinotecan (CPT-11) Preliminary results of a multicenter phase II study . [Abstract] Proc Am Soc Clin Oncol. 19:2000;319a.
39. Jacobs A.D., Otero H., Picozzi V., et al. A phase I/II study of gemcitabine (G) and docetaxel (D) in patients (Pts) with unresectable pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 19:2000;265s.
40. Louvet C., André T., Lledo P., et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma Final results of a GERCOR multicenter phase II study . J Clin Oncol. 20:2002;1512-1518.
41. Mendelsohn L.G., Shih C., Chen V.J., et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol. 26:(Suppl. 6):1999;42-47.
42. Miller K.D., Picus J., Blanke C., et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol. 11:2000;101-103.
43. Kindler H.L., Dugan W., Hochster H., et al. Clinical outcome in patients with advanced pancreatic cancer treated with pemetrexed/gemcitabine. [Abstract] Proc Am Soc Clin Oncol. 21:2002;125a.
44. Lawrence T.S., Eisbruch A., McGinn C.J., et al. Radiosensitization by gemcitabine. Oncology. 13:(Suppl. 5):1999;55-60.